Scott L Letendre Selected Research

Neurocognitive Disorders (Clerambault Syndrome)

10/2021	Higher CSF Ferritin Heavy-Chain (Fth1) and Transferrin Predict Better Neurocognitive Performance in People with HIV.
1/2020	HIV influences microtubule associated protein-2: potential marker of HIV-associated neurocognitive disorders.
12/2018	Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy.
6/2017	Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study.
4/2017	Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults.
1/2017	Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
12/2016	Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults.
11/2016	HIV-associated neurocognitive disorder is associated with HIV-1 dual infection.
4/2016	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.
1/2016	Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Scott L Letendre Research Topics

Disease

23	HIV Infections (HIV Infection) 01/2022 - 06/2010
19	Neurocognitive Disorders (Clerambault Syndrome) 10/2021 - 02/2008
15	Inflammation (Inflammations) 01/2022 - 06/2010
8	Acquired Immunodeficiency Syndrome (AIDS) 12/2019 - 05/2002
7	Cognitive Dysfunction 01/2022 - 09/2004
7	Infections 12/2016 - 01/2004
4	Coinfection 04/2016 - 04/2010
3	Substance-Related Disorders (Drug Abuse) 01/2019 - 11/2009
3	Gliosis 10/2018 - 12/2006
3	Dementia (Dementias) 04/2016 - 05/2002
3	Hepatitis C 02/2014 - 10/2005
2	Polyneuropathies (Polyneuropathy) 01/2022 - 04/2009
2	Neuralgia (Stump Neuralgia) 01/2022 - 01/2020
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 11/2015
2	Brain Injuries (Brain Injury) 04/2021 - 05/2015
2	Neuroinflammatory Diseases 11/2020 - 12/2016
2	Anemia 04/2016 - 02/2014
2	Malaria 09/2012 - 11/2009
1	Premature Aging 01/2022
1	Major Depressive Disorder (Major Depressive Disorders) 01/2022
1	Pain (Aches) 01/2022
1	Viremia 10/2021
1	Invasive Fungal Infections 01/2021
1	Frailty 11/2019
1	Wounds and Injuries (Trauma) 01/2019
1	Amyloid Plaque 10/2018
1	Cerebral Small Vessel Diseases 10/2018
1	Vascular Remodeling 02/2017
1	Encephalitis (Encephalitis, Rasmussen) 01/2017
1	Leukocytosis (Pleocytosis) 04/2016
1	Disease Progression 01/2016
1	Pharyngitis (Sore Throat) 10/2014
1	Vision Disorders (Hemeralopia) 01/2014
1	Mood Disorders (Mood Disorder) 12/2013
1	Neurobehavioral Manifestations 12/2013
1	Bipolar Disorder (Manic Depressive Psychosis) 12/2013
1	Vascular Diseases (Vascular Disease) 04/2010
1	Liver Diseases (Liver Disease) 10/2005
1	Leukoencephalopathies 05/2002

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2010
10	Methamphetamine (Desoxyn)FDA LinkGeneric 11/2019 - 01/2004
9	RNA (Ribonucleic Acid)IBA 11/2020 - 11/2009
5	Pharmaceutical PreparationsIBA 12/2020 - 09/2007
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2009
4	Biological ProductsIBA 04/2021 - 10/2005
4	Proteins (Proteins, Gene)FDA Link 07/2015 - 04/2010
3	Mitochondrial DNA (mtDNA)IBA 01/2022 - 11/2015
2	NeopterinIBA 01/2022 - 01/2016
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022 - 10/2005
2	Lipopolysaccharide ReceptorsIBA 01/2019 - 05/2015
1	Amyloid (Amyloid Fibrils)IBA 01/2022
1	Opioid Analgesics (Opioids)IBA 01/2022
1	8-Hydroxy-2'-DeoxyguanosineIBA 01/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2022
1	Amino Acids FDA Link 01/2022
1	Amitriptyline (Elavil)FDA LinkGeneric 01/2022
1	Transferrin (beta 2 Transferrin)IBA 10/2021
1	C-Reactive ProteinIBA 01/2021
1	Homovanillic AcidIBA 11/2020
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2020
1	Pain-FreeIBA 01/2020
1	fibrin fragment D (D-dimer)IBA 01/2019
1	TESIBA 01/2019
1	Tenofovir (Viread)FDA Link 10/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2017
1	Angiopoietin-2IBA 02/2017
1	Immunoglobulin G (IgG)IBA 12/2016
1	Zidovudine (Retrovir)FDA LinkGeneric 04/2016
1	FHDIBA 01/2016
1	Tryptophan (L-Tryptophan)FDA Link 01/2016
1	Protons (Proton)IBA 05/2015
1	Integrase InhibitorsIBA 07/2014
1	CytokinesIBA 07/2014
1	Retinaldehyde (Retinal)IBA 01/2014
1	AntibodiesIBA 09/2012
1	Cysteine (L-Cysteine)FDA Link 04/2012
1	Hepatitis C AntibodiesIBA 06/2011
1	Antiviral Agents (Antivirals)IBA 02/2011
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 04/2010
1	ApolipoproteinsIBA 04/2010
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2005
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2005
1	N-acetylaspartate (N-acetyl aspartate)IBA 01/2004

Therapy/Procedure

20	Therapeutics 01/2022 - 05/2002
16	Highly Active Antiretroviral Therapy (HAART) 12/2021 - 05/2002
8	Art Therapy 01/2022 - 02/2011
4	Activities of Daily Living (ADL) 01/2020 - 07/2010
1	Pain Management 01/2022